With BSEM’s revenues skyrocketing, game-changing partnerships, a successful capital raise, and the start of a crucial clinical trial for diabetic foot ulcers… this all reads like a recipe for tremendous shareholder value. 

Emerging MedTech company BioStem Technologies, Inc. (OTC: BSEM) is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. 

The company is capturing Wall Street’s attention as its share price has risen from around $1 in July of 2023 to as high as $7.00 by year-end. By the end of 2024, shares were nearly $30 a share. 

Zack’s Small Cap Research has a $35.50 price target on shares. What has Zack’s SCR had to say? “The company continues to show tremendous growth that is beating even our most optimistic projections.” Over the past year Zacks Small Cap Research has been very bullish on BSEM and has been lifting its price target several times. Could another price increase be on the way after BSEM’s preliminary revenues?

BSEM has recently announced record preliminary net revenue of $72.5 million for Q1 2025. This is a 73% increase compared to $41.9 million in Q1 2024. The company also ended the quarter with cash on hand at $26.7 million, an increase from $22.8 million on December 31st, 2024. This was the strongest first quarter in the company’s history! 

On the capital markets front, BSEM remains in active review with the SEC regarding its Form 10 registration and uplisting process, and it looks forward to completing this milestone and becoming listed on Nasdaq. Being listed on the NASDAQ would open up the stock to new investors, especially on the institutional front! 

Learn more about the little-known medtech company that may be on the verge of another price target increase from Zacks SCR!